Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.35 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 4/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | CTRC | Q99895 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765965 | 0.83 | P2RX3 (0.34) | AVPR1BCASP1F2ELANECMA1 | |
| SCHEMBL30765575 | 0.82 | AVPR1B (0.35) | AVPR1BPOLBKMT2AMEN1 | |
| SCHEMBL30765769 | 0.81 | NTRK1 (0.40) | AVPR1BTSHRCASP1F2ELANE | |
| SCHEMBL30765838 | 0.79 | CASP1 (0.41) | CASP1ELANEPOLBCMA1CTRC | |
| SCHEMBL30765548 | 0.77 | F2 (0.39) | AVPR1BTSHRCASP1F2ELANE | |
| SCHEMBL30765465 | 0.73 | LMNA (0.39) | CASP1ELANEKMT2AMEN1 | |
| SCHEMBL30765579 | 0.73 | F3 (0.39) | CASP1F2PRSS1CMA1CTRC | |
| SCHEMBL30765926 | 0.72 | GAA (0.52) | AVPR1BCASP1ELANEPOLBKMT2A | |
| SCHEMBL30765805 | 0.70 | LMNA (0.39) | AVPR1BCASP1ELANECMA1KMT2A | |
| SCHEMBL30765916 | 0.70 | CMA1 (0.41) | CASP1ELANEPOLBCMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |